B+
Bull case
25%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
QTTB
Q32 BioFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The core bull case is that Q32 has narrowed the story to bempikibart, completed SIGNAL-AA Part B enrollment, and still guides to a mid-2026 topline readout while runway extends into late 2027 if management assumptions hold [#10-K-2026-03-10] [#PR-2026-03-10].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
ATM usage could create incremental dilution and pressure sentiment.
Momentum
84
Value
55
Sentiment
4
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.50 · Bull $10.00 · Bear $2.50Analysis 2026-04-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $41.00
Why
Momentum84 · Δ7d -12.0
Value55 · Δ7d 0.0
Sentiment4 · Δ7d +0.5
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • ATM usage could create incremental dilution and pressure sentiment.
- • Mid-2026 SIGNAL-AA Part B results may disappoint or slip.
- • The bear case is that this remains a one-asset, low-coverage biotech with a negative deterministic prior, modest evidence quality, and explicit dependence on future capital beyond current runway; any readout delay, weaker efficacy, or use of the ATM could pressure shares materially [#8-K-2026-03-27] [#10-K-2026-03-10].
Catalyst clock
2026-07-15
SIGNAL-AA Part B 36-week topline data in mid-2026
Lead driver: Value · See fundamentals
Momentum
84
9% active weight
Current posture
7d trendSoftening
Δ7d
-12.0
Δ21d
-14.6
Value
55
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+10.6
Sentiment
4
62% active weight
Current posture
7d trendFlat
Δ7d
+0.5
Δ21d
+0.5
Why this grade
Composite grade F. Momentum 84.4 / Value 54.8 / Sentiment 3.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-04-15. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-04-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$474.82M
Beta
0.17
Shares Out
29.77M
P/E (TTM) · Derived
6.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-11.10
Rev YoY
-100.0%
EPS YoY
-43.5%
Gross Margin
+99.3%
Op Margin
-
Net Debt
-$32.95M
Current Ratio
20.28
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data